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An important consideration in the design of vaccines to prevent HIV-l infection effective against different strains is the 
amino acid sequence conservation of antigenic determinants. Even one amino acid change can destroy the antigenicity 
of a site for the antibody or T-cell receptor. The comparisons of predicted T- and B-cell epitopes between human HIV-I, 
HIV-2 and monkey SIVt.,*c AIDS viruses are presented. The three major gene products (envgag and pol) were examined. 
A number of epitopes were identical between strains of HIV-l. Our analysis highlights the problem of designing an effec- 
tive HIV-I and HIV-2 vaccine and also the problem of testing human vaccines in monkey models. 
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1. INTRODUCTION 
There is no effective vaccine for the prevention 
of AIDS (Acquired Immune Deficiency Syn- 
drome). In designing a vaccine for this disease, 
consideration should be given to epitope sequence 
variation between strains of the human im- 
munodeficiency virus type-l [l-4] because a suc- 
cessful vaccine should be effective against a range 
of isolates. Furthermore, if epitopes were iden- 
tified which are shared between human im- 
munodeficiency virus type-l (HIV-l) and type-2 
(HIV-2) [5] a common HIV vaccine for these two 
strains could be feasible. SIVMAC causes an AIDS- 
like disease in rhesus macaque monkeys [6]; 
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therefore, if a section of the chain is conserved be- 
tween HIV-l, and SIVMAC it could lead to testing 
of the effect of HIV-l peptides in monkeys. In this 
paper we use the nucleotide-derived protein se- 
quences of HIV-l strains, HIV-2 and SIVMAC to 
predict areas of sequence homology which contain 
antigenic B-cell and T-cell determinants. We con- 
sider the three major gene products: gag, pol and 
env. 
Research has concentrated on the development 
of an envelope vaccine [7-111 because certain 
retroviral envelope proteins [12] do confer 
antibody-mediated protection against viral 
challenge in animals. So far HIV-l envelope vac- 
cines [13] have failed to protect chimpanzees 
against infection. We have suggested [14,15] that 
the search for a vaccine should not only include 
env, but also gag and possibly pol gene products. 
This proposal is based upon the observation [16] 
that T-cell epitopes of the core protein of hepatitis- 
B virus induce T-cell help of B lymphocytes. This 
results in the production of antibody against the 
surface antigen. Furthermore, preliminary ex- 
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Fig.1. The alignment of gag HIV-l, HIV-2 and SIVMM sequences. The ‘*’ on the top row indicates identities between HIV-l and 
SIVMAC. ‘*’ on the bottom row indicates identities between HIV-l and HIV-2. A ‘ + ’ denotes the core prediction for the B epitopes 
where the number gives the rank peak height. A ‘ - ’ illustrates predicted positions for T epitopes by both the DeLisi and Berzofsky 
(BD) method and the Rothbard and Taylor (RT) method. A ‘v’ denotes an inter-strain variable position and a ‘g’ indicates where it 
was necessary to insert a gap into the alignment. 
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Fig. 1 (contd). 
periments [ 17,181 suggest the core antigen of 
hepatitis-B may induce protection in chimpanzees 
against viral challenge. Whether any of this applies 
to an AIDS vaccine is unknown, but T-cell- 
mediated immunity against HIV-l env and gag 
proteins, both helper and cytotoxic, has been 
recorded [19-211. In addition antibody against 
HIV-l core (gag) antigen disappears, in many pa- 
tients, prior to the onset of the disease, but it is not 
clear whether this indicates that an anti-gag im- 
mune response prevents the onset of the disease 
[22] or whether it merely accompanies progression 
towards AIDS. 
In this paper, we have performed epitope predic- 
tions for T- and B-cell sites. T-cells may recognize 
different [23] parts of the chain from B cells but 
there is evidence that protective B epitopes of in- 
fluenza virus overlap with T epitopes [24]. 
2. MATERIALS AND METHODS 
The studies were carried out on the HIV-lr~v virus, the si- 
mian virus (SIVMX) and HIV-2~ou. The sequences for the 
HIV-l virus were obtained from the Protein Information 
Resource Databank (see [15] for further details). The sequences 
for other HIV-l strains, SIVMAC, HIV-2 were obtained from the 
Los Alamos National Database [25]. 
2.1. Sequence variation between the HIV-I strains 
Ten gag, 13 env and 8 pol HIV-l sequences were aligned by 
the method of Barton and Sternberg [26] to investigate inter- 
strain variation. In figs l-3 a ‘v’ denotes inter-strain variation 
for HIV-l and a ‘g’ denotes the introduction of a gap into the 
alignment. In tables 1 and 2, %SI denotes the identity between 
HIV-l isolates within a predicted epitope. 
2.2. Sequence variation between HIV-l, SIVMAC and HIV-2 
A multiple alignment of HIV-l, SIVMAC, and HIV-2 se- 
quences was obtained [26]. In figs l-3 an identity between 
HIV-l and SIVMAC is indicated by a * on the top row, while 
identities between HIV-l and HIV-2 are indicated by a * on the 
bottom row of the alignment. 
2.3. Principle of analyses 
Predictions of B-cell and T-cell epitopes (see sections 2.4 and 
2.5) were performed on the HIV-l, HIV-2 and SIVMA~ se- 
quences (figs l-3). These figures provide information to guide 
vaccine design based on many different criteria. For example, 
peptides might be selected on sequence conservation or on 
regions of high variation. In this paper we analyse conservation 
of sequences and of predicted antigenic epitopes. Predicted 
epitopes were taken to be at least 12 residues long as peptides 
of this length have frequently been shown to contain an epitope 
127-291. This analysis, of course, considers only linear 
epitopes. 
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Fig.2 (contd). 
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Fig.2. The alignment of pol HIV-l, HIV-2 and SIVMAC. 
The identity between HIV-l and HIV-2 was calculated for 
positions in the HIV-l predicted epitope irrespective of whether 
an epitope was predicted in HIV-2 (denoted as HIV-l ‘701-2). 
Similarly HIV-l %1-S denotes the identity between HIV-l and 
SIVMAC. Other measures of sequence identity between epitopes 
were considered but these did not markedly alter the results. 
Tables 1 and 2 list all B and T epitopes with %SI of 100%. 
Epitopes with 1 or 2 sequence variable positions are reported in 
the text. 
2.4. B epitopes 
B-cell epitopes were predicted by the algorithm of Hopp and 
Woods [30] which searches for a local maximum in a 
hydrophilicity profile smoothed over 6 residues. Hydrophilic 
peaks were selected in order of decreasing hydrophilicity. The 
6 residue predicted B-epitope core (denoted by a ‘ + ’ in the 
figures) was extended on either side by 3 residues to obtain a 12 
residue long polypeptide (called the predicted epitope). In our 
previous study [14,15] we concentrated on B epitopes that did 
not occur within a predicted secondary structure. Because of the 
sequence variation between HIV-l, HIV-2 and SIVMAC, dif- 
ferent predictions of secondary structure were obtained (results 
not shown). Given the limited accuracy of secondary structure 
predictions, a structural restriction on B epitopes would unduly 
complicate the analysis. 
2.5. T epitopes 
Two algorithms to predict T-cell epitopes were applied, and 
the results denoted by a ‘ - ’ in the figures. (a) The method of 
DeLisi and Berzofsky [23] calculates the amphipathicity of a 
section 11 residues long and regions with an o-helix periodicity 
are identified as possible T-cell epitopes. (b) The procedure of 
Rothbard and Taylor [29] scans for a linear pattern composed 
of a charged residue or a glycine, followed by 2 or 3 
hydrophobic amino acids and terminated by a charged or polar 
residue. 
The predicted T epitope regions can be longer or shorter than 
the 12 residues defined for the B epitopes. In this paper, the 
core prediction was extended towards the N- and C-termini to 
a polypeptide of minimum 12 residues or to as long as T 
epitopes positions were predicted by either method and overlap- 
ped by at least one position. 
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Fig.3 (contd). 
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Fig.3. The alignment of env HIV-l, HIV-2 and S1V~ac. 
Table 1 
The predicted B epitopes with %SI = 100 in HIV-I 
HIV-l HIV-2 SIVMAC 
Epitope Epitope Epitope HIV-l Epitope HIV-l 
numbers sequence numbers %l-2 numbers 0701-s 
PO1 
128-139 
265-276 
303-314 
421-432 
ALLDTGADDTVL 
FAIKKKDSTKWR 
GLKKKKSVTVLD 
PDKKHQKEPPFL 
128-139 
265-276 
301-313 
416-427 
420-43 1 
503-514 
67 
83 
67 
58 
58 
50 
75 
33 
128-139 67 
265-276 75 
301-312 67 
419-430 58 
507-518 LAENREILKEPV 
746-757 ISGNEQVDKLVS 
968-979 IATDIQTKELQK 
503-514 33 
67 
25 
Gag 
230-241 
288-299 
Em 
294-305 
QMREPRGSDIAG 229-240 92 229-240 83 
LDIRQGPKEPFR 288-299 83 288-299 75 
STQLLINGSLAE 50 299-310 50 
The epitope numbers denote the positions of the predicted epitopes in the figures. The 
HIV-l epitope sequence is given. If an epitope is found in corresponding regions in HIV-2 
or SIVMA~ then their position numbers are given. %HIV-1 is defined in procedures 
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Table 2 
The predicted T epitopes with %SI = 100% in HIV-l 
HIV-I HIV-2 SIVMAC 
Epitope Epitope Epitope HIV-1 Epitope HIV-l 
numbers sequence numbers % 1-2 numbers %1-S 
Pol 
123-134 QLKEALLDTGAD 123-134 75 123-143 75 
150-161 KMIGGIGGFIKV 150-161 67 147-160 67 
293-304 EVQLGIPHPAGL 293-304 92 293-304 100 
314-325 DVGDAYFSVPiD 314-325 83 314-325 83 
502-513 EAELELAENRJZI 67 58 
615-626 IPEWEFVNTPPL 615-626 75 615-626 75 
704-715 QYALGIIQAQPD 50 706-717 50 
796-807 VAKEIVASCDKC 797-808 58 799-810 75 
808-819 QLKGEAMHGQVD 808-819 67 808-819 67 
840-85 1 AVHVASGYIEAE 840-851 92 840-851 92 
901-912 QEFGIPYNPQSQ 901-912 83 901-912 75 
Gag 
347-359 LEEMMTACQGVG 346-357 92 346-357 92 
Env 
42- 53 VPVWKEAT-TTLF 67 58 
111-124 LWDQSLKPCVKLTP 103-116 71 103-116 64 
December 1988 
3. RESULTS 
The HIV-2 and SIVM:AC sequences are far more 
homologous to one another than either are to 
HIV-l. We pay particular attention to regions 
where B and T epitopes overlap because it has been 
shown that protective epitopes in influenza virus 
contain overlapping B and T epitopes [31]. All 
residue numbers refer to the alignment numbers 
used in the figures. 
3.1. Analysis of the gag gene 
Fig.1 illustrates the alignment and prediction of 
the gag gene product. 50% of residues are con- 
served between HIV-l, SIVMAC, and HIV-2. Ten B 
epitopes were located that had 2 or less HIV-l 
inter-strain variable positions. Two B epitopes 
were found in which there was total sequence iden- 
tity between the thirteen HIV-l isolates (100% SI). 
Both regions have corresponding HIV-2 and 
SIVMA~ predicted B epitopes with reasonable se- 
quence conservation to HIV-l. Part of the 
288-299 B epitope region (LDIRQGPKEPFR) has 
also previously been identified as a promising can- 
didate for vaccine studies [ 14,151. There are four B 
epitopes with one inter-strain variable position 
18 
(15-26, 158-169, 290-301, 480-492). All but 
480-492 have overlapping HIV-2 and SIVMA~ 
predicted B epitopes. Four B epitopes had two 
inter-strain variable positions (20-3 1, 95-l 06, 
99-113,308-419). Only 20-31 and 308-319 had a 
HIV-2 B epitope associated with them while 
20-31, 95-106 and 308-319 a SIVMAC B epitope. 
Only the region 20-31 has a HIV-2 and SIVMAC se- 
quence with high sequence identity to HIV-l. 
Thus, although gag contains 2 B epitopes that have 
no inter-strain variability, they are not identical to 
either HIV-2 or SIVMAC. Therefore if one residue 
difference disrupts the antigenicity of the epitopes, 
it is not possible to produce a HIV-l B epitope that 
will be effective against HIV-2 infection or that 
could be tested in SIVMAC. However, if peptides 
shorter than 12 residues are considered then there 
is an epitope (15-26 in HIV-l) that has 8 residues 
for which there is 100% sequence identity with 
SIVMAC . 
Only one T epitope (347-358) has no inter-strain 
variation. In HIV-2 and SIVMAC there are cor- 
responding T epitopes in this region and the se- 
quence homology to HIV-l is high. Eight T 
epitopes are found that have one inter-strain 
variable position (73-84, 156-167, 170-181, 
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198-209, 215-226, 273-284, 335-346, 365-376) 
and further 8 T epitopes are located that have 2 
inter-strain variable positions (96- 107, 187- 198, 
207-218, 260-271, 291-307, 311-322, 415-426, 
479-491). Of the 17 T epitopes with less than three 
sequence variations between HIV-l strains, 13 are 
in the p24 protein. 
The B epitope in position 288-299 has a T 
epitope region overlapping at positions 291 to 307 
which has two inter-strain variable positions. The 
only T epitope with no inter-strain variation 
(347-358) has no overlapping predicted B epitope. 
3.3. Analysis of the pol gene 
The pol sequence is as well conserved as the gag, 
49% identity between the three aligned sequences 
and there are a considerable number of B and T 
epitopes found with no inter-strain variation. 
Seven B epitopes are found with 100% SI. But 
none have HIV-l %l-2 and HIV-I 0701-S of 100070. 
However, one HIV-l B epitope (1018-1029) has 8 
residues that are fully conserved to the predicted B 
epitope in SIVMMAC. Ten B epitopes were located 
with one inter-strain variable position (220-23 1, 
230-241, 281-292, 322-333, 499-510, 522-533, 
914-925,925-936, 1012-1023, 1018-1029). Six of 
these had overlapping B epitopes in HIV-2 and on- 
ly 4 in SIVMAC. 
A total of 11 T epitopes are identified in the pol 
product that has no inter-strain variation. One of 
these, epitope 293-304 has lOO(110 sequence identity 
to SIVMAC, which also has a T epitope predicted. 
Between HIV-l and HIV-2 there is only one 
residue difference and also a T epitope is predicted 
in the same position. This T epitope prediction 
overlaps with a B epitope prediction (303-314) 
that also has no inter-strain variable position. Fur- 
ther 10 T epitopes are found that have only one 
inter-strain variable position (273-284, 284-295, 
478-489, 512-524, 683-694, 749-760, 780-791, 
910-921, 1019-1030, 1026-1039). 
3.4. Analysis of the em gene 
There is a low homology (28% identity) between 
the three env sequences. One B epitope is found 
that has no inter-strain variation. However, this B 
epitope has no corresponding prediction in HIV-2 
and although there is an overlapping B epitope 
prediction in SIVMAC the sequence homology is 
very low. No B epitopes with only one inter-strain 
variable position were found. There are five B 
epitopes with two inter-strain variable positions 
(100-111, 516-527, 539-550, 546-558,628-639). 
Only two T epitopes that are conserved between 
the HIV-l isolates are found in the env product. 
One (42-53) has no corresponding T epitope 
prediction in either HIV-2 or SIVMAC. The other 
(1 1 1 - 124) has overlapping T epitope predictions in 
HIV-2 and SIVMAC but the sequence homology 
between these and HIV-l is low. Three T epitopes 
with one inter-strain variable position (37-48, 
521-532, 586-600) and nine T epitopes with two 
inter-strain variable positions (283-297, 527-538, 
535-546, 544-556, 599-610, 606-617, 627-638, 
643-654, 764-757) were located. None showed 
high sequence homology to HIV-2 or SIVMAC. 
4. DISCUSSION AND CONCLUSIONS 
Antigen prediction techniques were used to 
analyse the potential effect of HIV epitope se- 
quence variability on AIDS vaccine design. This 
study, being based on predictions, is intended as a 
guide for experimental vaccine design. For the B- 
epitopes, the predictions with the higher rank 
order of hydrophilicity (figs l-3) will be more ac- 
curate [30]. The highest peak is nearly always an- 
tigenic [30]. For example, the env B epitope 
787-800 is antigenic [32] and contains two 
predicted epitopes of rank 1 and 3. The accuracy 
of T epitope predictions has been less well studied. 
However, two predicted T epitopes [15] have 
subsequently been shown [33] to be part of ex- 
perimentally verified T-cell sites (peptides 
105-117, 465-480). Env, gag and pol each code 
for several protein products that result from pro- 
teolytic cleavage of the initial polyprotein gene 
product. If a predicted epitope includes a cleavage 
site then this epitope might not be antigenic. 
However, in cells infected with a related retrovirus 
(equine infectious anemia virus), uncleaved and 
partially cleaved polyproteins have been shown to 
be antigenic [34]. Thus peptides that span protease 
cleavage sites might be antigenic. Accordingly we 
have included them in this study but the location of 
these cleavage sites should be considered in the in- 
terpretation of experimental. results. 
We addressed three specific problems. Firstly, 
we investigated the likelihood of finding a single 
HIV-l vaccine which might protect an individual 
19 
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against a range of HIV-l isolates. In other 
microorganisms neutralising antibody against sur- 
face antigens, such as envelope, confers protection 
and accordingly the most promising candidates for 
de novo protection against HIV infection are the 
env proteins. In env there was only one predicted 
B epitope (294-305) which was found to be con- 
served between the 13 isolates considered. The 
hydrophilicity is ranked 17th, which indicates a 
low accuracy of prediction. In contrast, the B 
epitope 787-800, which has the highest rank, is 
poorly conserved between HIV-l strains and only 
5 out of its 14 residues were found in all the isolates 
which were studied. This suggests that env from 
one HIV-l strain is unlikely to induce protective 
antibody-mediated immunity against a range of 
wild HIV-l strains unless the 294-305 epitope is 
effective as a vaccine. In gag two B epitopes are 
conserved between all strains but in pol seven B 
epitopes are conserved. In viruses, a major compo- 
nent of the T-cell response is directed at internal 
proteins. In HIV-l two T epitopes are fully con- 
served in all strains for env, one for gag and 11 for 
pol. If a polypeptide from a single strain is to be 
effective against all HIV-l isolates in an outbred 
population such as man, then this analysis in- 
dicated T epitopes from pol as the most promising 
candidate. The analysis highlights the need in 
animal studies to challenge with the same strain of 
virus which was used to immunize. A problem with 
this approach might occur if epitope variation were 
to occur early after infection. 
Secondly, we assessed the feasibility of using 
HIV-l antigenic peptides in a monkey AIDS 
model, by searching for sections of the chain which 
are conserved between HIV-lr~v and SIVMAC. In 
env and gag, no predicted sites were 100% iden- 
tical between HIV-l and SIVMAC. Pol had only one 
conserved site. Thus it is unlikely that HIV-l pep- 
tides will confer protection against SIVMAC 
challenge in the monkey if complete epitope se- 
quence conservation is required. 
Thirdly, the prospect for a single HIV-l vaccine 
which would protect an individual against HIV-2 
was addressed. In env, gag and pol no predicted B- 
cell and T-cell sites were 100% identical between 
HIV-l and HIV-2, and so a single effective 
HIV-l/HIV-2 vaccine is unlikely to emerge. 
Apart from T epitope based predictions in pol, 
a cocktail of peptides from different viral strains 
20 
may be required as an effective vaccine against 
HIV-l. It is unlikely that this cocktail will be effec- 
tive against HIV-2 and so additional peptides 
based on the HIV-2 virus will need to be intro- 
duced. The HIV-l vaccines would be difficult to 
test in rhesus macaque monkeys because of con- 
siderable sequence variation between HIV-l and 
SIVMAC . 
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